Schedule 13D ownership disclosure

Monopar Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 61023L207

Event date: 2026-01-28

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Tactic Pharma LLCReported CIK 0001727357

    Shares: 0.00 · Class: 0.0%

  • Robinson ChandlerReported CIK 0001727334

    Shares: 307,370.00 · Class: 4.5%

  • Brown Michael JReported CIK 0001035909

    Shares: 124,629.00 · Class: 1.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001437749-26-002528
Form type
SCHEDULE 13D/A
Filer
Monopar Therapeutics
CIK
CIK 1645469
Filed
Jan 30, 2026
Reporting period
Jan 28, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub